| Literature DB >> 27609293 |
Jung-Ah Lim1, Soon-Tae Lee1, Tae-Joon Kim1, Jangsup Moon1, Jun-Sang Sunwoo2, Jung-Ick Byun3, Keun-Hwa Jung1, Ki-Young Jung1, Kon Chu4, Sang Kun Lee5.
Abstract
The aim of this study was to analyze the clinical presentation and provocation factors of rhabdomyolysis in anti-NMDAR encephalitis. Among the 16 patients with anti-NMDAR encephalitis in our institutional cohort, nine patients had elevated CK enzyme levels and clinical evidence of rhabdomyolysis. Rhabdomyolysis was more frequent after immunotherapy. The use of dopamine receptor blocker (DRB) increased the risk of rhabdomyolysis. None of the patients without rhabdomyolysis received DRBs. Rhabdomyolysis is a frequent complication in anti-NMDAR encephalitis and more common after immunotherapy and the use of DRBs increases the risk. Therefore, DRBs should be administered carefully in patients with anti-NMDAR encephalitis.Entities:
Keywords: Autoimmune encephalitis; Encephalitis; NMDA; Rhabdomyolysis
Mesh：
Substances：
Year: 2016 PMID： 27609293 DOI： 10.1016/j.jneuroim.2016.08.002
Source DB: PubMed Journal: J Neuroimmunol ISSN： 0165-5728 Impact factor: 3.478